As AI permeates clinical analytics, Perceptive Advisors bets $40M into a storied player in the field
When it comes to using artificial intelligence to speed up drug discovery and development, the former may be grabbing the most attention with the crop of AI upstarts vowing to find better candidates faster and cheaper, but the possibility of accelerating existing clinical programs is equally enticing — if less visible — to the biopharma industry.
That’s at least part of the rationale behind Perceptive Advisors’ $40 million infusion into Saama, a software company selling a clinical data analytics platform powered by AI.
The firm has been around since 1997, curating an ever-expanding stream of operational and patient data from various sources and of various types — and churning out insights that it says can compress the clinical development timeline.
“We intend to use the proceeds of this financing to strengthen our ecosystem of pharma and biotech partners, academia, data providers and CROs, and build a suite of collective innovations leveraging our award-winning LSAC platform,” said Suresh Katta, founder and CEO of Saama Technologies in a Monday statement.
Perhaps a reflection of the global nature of that ecosystem, Saama has its headquarters in Campbell, CA but keeps offices in Arizona, Ohio, New Jersey in the US, two cities in India, and one each in the UK and Switzerland.
Optimization and efficiency are goals that everyone working in R&D can rally around, and AI promises to be a tool that gets more powerful by the hour. In a recent forward-looking report, IQVIA predicted that the adoption of machine learning and AI will grow significantly over the coming 5 years. AI and ML will have an impact on clinical as well as commercial settings, driving drug management and identifying patients. And as data sets continue to grow in size, the information and analysis that they will provide will grow in value, further driving adoption.